Q32 Bio (QTTB)
NASDAQ:QTTB
QTTB Stock Chart & Stats
$6.42
-$0.23(-6.52%)
At close: 4:00 PM EST
$6.42
-$0.23(-6.52%)
Day’s Range― - ―
52-Week Range$1.35 - $8.05
Previous CloseN/A
Volume113.57K
Average Volume (3M)253.90K
Market Cap
$93.92M
Enterprise Value$41.84M
Total Cash (Recent Filing)$48.30M
Total Debt (Recent Filing)$11.18M
Price to Earnings (P/E)0.2
Beta0.59
Next Earnings
May 07, 2026EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.58
Shares Outstanding14,629,463
10 Day Avg. Volume330,159
30 Day Avg. Volume253,899
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.97
Price to Sales (P/S)0.76
P/FCF Ratio-1.69
Enterprise Value/Market Cap0.45
Enterprise Value/Revenue0.78
Enterprise Value/Gross Profit0.78
Enterprise Value/Ebitda2.19
Forecast
1Y Price Target
$14.33Price Target Upside123.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.58
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet RepairMaterial reduction in debt and a large increase in equity materially lower near-term liquidity risk and improve financial flexibility to fund clinical milestones. This strengthens the company’s ability to support R&D and trials over the next several quarters, though structural stability should be monitored.
Capital Access Via ATM And Registered OfferingFlexible equity programs and a recent registered direct offering provide durable optionality to finance operations and development without committing to a single dilutive event. Ongoing access to capital supports clinical timelines and reduces immediate runway pressure versus having no programmatic funding.
Clinical-stage Biologics PipelineA focused pipeline of monoclonal antibodies targets large, structurally durable markets (autoimmune/inflammatory disorders). If clinical progress continues, successful trials would create durable revenue streams and competitive positioning typical of approved biologics, supporting long-term franchise value.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow means the company remains reliant on external financing to advance its pipeline. Continued burn pressures strategic choice and may force dilutive raises or cap structure trade-offs that can delay development or constrain long-term value creation.
Effectively Zero RevenueA lack of recurring commercial revenue leaves the business model dependent on milestone financing and capital markets. This reduces visibility into sustainable margins and cash returns, lengthens the timeline to self-sufficiency, and increases sensitivity to funding availability and trial outcomes.
Volatile Earnings QualityA one-off improvement in reported profitability without supporting revenue growth suggests earnings are driven by non-operational items. This undermines predictability of future profits, complicates forecasting, and limits confidence that positive earnings mark a durable shift in operating performance.
Q32 Bio News
QTTB FAQ
What was Q32 Bio’s price range in the past 12 months?
Q32 Bio lowest stock price was $1.34 and its highest was $8.04 in the past 12 months.
What is Q32 Bio’s market cap?
Q32 Bio’s market cap is $93.92M.
When is Q32 Bio’s upcoming earnings report date?
Q32 Bio’s upcoming earnings report date is May 07, 2026 which is in 35 days.
How were Q32 Bio’s earnings last quarter?
Q32 Bio released its earnings results on Mar 10, 2026. The company reported $4.58 earnings per share for the quarter, beating the consensus estimate of -$0.86 by $5.44.
Is Q32 Bio overvalued?
According to Wall Street analysts Q32 Bio’s price is currently Undervalued.
Does Q32 Bio pay dividends?
Q32 Bio does not currently pay dividends.
What is Q32 Bio’s EPS estimate?
Q32 Bio’s EPS estimate is -0.68.
How many shares outstanding does Q32 Bio have?
Q32 Bio has 14,629,463 shares outstanding.
What happened to Q32 Bio’s price movement after its last earnings report?
Q32 Bio reported an EPS of $4.58 in its last earnings report, beating expectations of -$0.86. Following the earnings report the stock price went up 17.451%.
Which hedge fund is a major shareholder of Q32 Bio?
Currently, no hedge funds are holding shares in QTTB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Q32 Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.33 (123.21% Upside)
$14.33 (123.21% Upside)
Blogger Sentiment
Bullish
QTTB Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $75.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 18.2%
Last 30 Days ▲ 31.0%
Last 30 Days ▲ 31.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
283.59%
12-Months-Change
Fundamentals
Return on Equity
1630.23%
Trailing 12-Months
Asset Growth
-33.09%
Trailing 12-Months
Company Description
Q32 Bio
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
QTTB Stock 12 Month Forecast
Average Price Target
$14.33
▲(123.21% Upside)
Technical Analysis
Tempest Therapeutics
―
PDS Biotechnology
―
Grace Therapeutics
―
CalciMedica
―
Senti Biosciences
―
Ownership Overview
3.06% Insiders
2.72% Mutual Funds
48.61% Other Institutional Investors
43.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---